Abstract
The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.
| Original language | Italian |
|---|---|
| Pages (from-to) | 101-103 |
| Number of pages | 3 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 129-130 |
| Publication status | Published - 2005 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile. / Boero, G.; Specchio, N.; Gambardella, A.; Giallonardo, A. T.; Michelucci, R.; Fattouch, J.; Di Bonaventura, C.; La Neve, A.; Specchio, L. M.
In: Bollettino - Lega Italiana contro l'Epilessia, No. 129-130, 2005, p. 101-103.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile
AU - Boero, G.
AU - Specchio, N.
AU - Gambardella, A.
AU - Giallonardo, A. T.
AU - Michelucci, R.
AU - Fattouch, J.
AU - Di Bonaventura, C.
AU - La Neve, A.
AU - Specchio, L. M.
PY - 2005
Y1 - 2005
N2 - The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.
AB - The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.
KW - Juvenile Myoclonic Epilepsy
KW - Levetiracetam
KW - Open-label study
UR - http://www.scopus.com/inward/record.url?scp=33645216335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645216335&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:33645216335
SP - 101
EP - 103
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 129-130
ER -